Abstract
Purpose: To explore the clinical features associated with stent eccentricity and reveal the impact of stent eccentricity on the risk of 1-year restenosis after femoropopliteal stent implantation for symptomatic atherosclerotic peripheral artery disease (PAD). Materials and Methods: The clinical database of a multicenter prospective study was used. It registered 2,018 limbs of 1,766 patients in whom intravascular ultrasound (IVUS)-supported femoropopliteal endovascular therapy (EVT) for symptomatic atherosclerotic PAD was planned from November 2015 to June 2017. The study included 1,233 limbs of 1,088 patients implanted with a bare nitinol stent, drug-eluting stent (DES), or stent graft and administered ≥2 antithrombotic drugs. The stent eccentricity was evaluated using IVUS, calculated as [(maximum diameter) / (minimum diameter) − 1] at the cross-sectional segment with the lowest lumen area after stent implantation. Results: Chronic total occlusion and bilateral arterial calcification (peripheral artery calcification scoring system Grades 3 and 4) were positively associated with stent eccentricity, whereas renal failure while receiving dialysis, DES use, and stent graft use were negatively associated with stent eccentricity (all P < .05). Stent eccentricity was associated with an increased risk of 1-year restenosis (odds ratio [OR], 1.18; 95% CI, 1.01–1.37; P = .034). However, after adjustment for lesion severity and implanted stent types, the association was no longer significant (OR, 1.07; 95% CI, 0.91–1.24; P = .43). Conclusions: Stent eccentricity was not significantly associated with the risk of 1-year restenosis after femoropopliteal EVT.
| Original language | English |
|---|---|
| Pages (from-to) | 1089-1096 |
| Number of pages | 8 |
| Journal | Journal of Vascular and Interventional Radiology |
| Volume | 33 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2022 Sept |
Bibliographical note
Funding Information:The authors would like to thank all IVORY investigators and the clinical research coordinators of the participating centers for their efforts toward data collection. The IVORY study is sponsored by the following companies (in alphabetical order): Boston Scientific Japan K.K.; The Orbusneich Foundation; Johnson & Johnson K.K.; Medicon Inc.; Medtronic Japan Co., Ltd.; MSD K.K.; Otsuka Pharmaceutical Co., Ltd.; Terumo Corp.; and W.L. Gore & Associates, Co., Ltd. The funding companies played no role in the design of the study; the selection of the enrolled patients, treatment strategies, revascularization procedures and equipment; or the collection, analysis, and interpretation of the data.
Funding Information:
The authors would like to thank all IVORY investigators and the clinical research coordinators of the participating centers for their efforts toward data collection. The IVORY study was sponsored by the following companies (in alphabetical order): Boston Scientific Japan; The Orbusneich Foundation; Johnson & Johnson; Medicon; Medtronic Japan; MSD; Otsuka Pharmaceutical; Terumo; and W.L. Gore & Associates. The funding companies played no role in the design of the study; the selection of the enrolled patients, treatment strategies, revascularization procedures and equipment; or the collection, analysis, and interpretation of the data.
Publisher Copyright:
© 2022 SIR
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine